Out of the blue this past week we lost Kevin McCormack of CIRM to a heart attack. When I first heard, my reaction was that can’t be, but it is. About Kevin McCormack If you aren’t familiar with him, Kevin was officially Director of Patient Advocacy at our state’s Stem Cell Agency. However, he was […]
Weekly reads: Kevin McCormack passes, HSCs & RXR, Ethics Read More »
We’ll start with a story related to possible research misconduct, Stanford’s President Marc Tessier-Lavigne, and Science Magazine. In some ways the news on Science itself could be the bigger long-term story. Marc Tessier-Lavigne pub investigation, Science oops moment Here’s some of the coverage: Stanford investigates potential misconduct in president’s research, Science. Multiple publications of Marc Tessier-Lavigne
Weekly reads: Marc Tessier-Lavigne probe, Neuralink on the brain, Ras unchained Read More »
I get a lot of questions about stem cells for ALS and more recently people have been specifically interested in NurOwn from BrainStorm Cell Therapeutics. Recently, the FDA denied BrainStorm’s request for a BLA for NurOwn. The company felt its Phase III trial was encouraging. It sounds like they will move forward with a follow-up
Weekly reads: NurOwn, key gene screen, MS, Croce mess Read More »
If you’ve never heard of the KRAS G12C mutation, it’s a particularly frightening mutation present in numerous cancers. Like the MYC oncogene, many people view mutations in RAS as undruggable, but new efforts show some glimmers of hope. The drug Sotorasib has been approved by the FDA to target the KRAS G12C mutation. Here’s a
Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs Read More »
Histone proteins such as histone H3 are often popping up in science writing and news sometimes includes specific modified forms of H3 including one that we scientists call H3K27me3. What is in this article What is H3K27me3? | The histone code | H3K27ac and H3K27me3 function | H3K27 and human disease | References The goal of today’s post
Histone code series: H3K27me3 & H3K27ac functions & roles in diseases like DIPG Read More »
About 1 million people are living with multiple sclerosis in the U.S. alone with millions of other cases around the world so a huge effort has gone into trying to find new approaches to the disease including stem cells for MS. We’ll start our weekly recommended reads by talking about a new paper on MS
Stem cells for MS & other weekly reads: CRISPR, COVID & a bat cave, Huntington’s Read More »
When we hear the word senile we might think stereotypically of an older person who has cognitive impairment, but some argue that senility can apply to cells too as they age and that such cells can be targeted by drugs called senolytics. Unfortunately, the supplements industry has picked up on this idea to sell iffy
Recommended reads: senolytics, cow iPS cells, big CIRM royalty Read More »
The big news of the week was the launch of Altos labs and their ambitious plan to tackle aging through cell therapies. Altos has recruited a large number of top cell biologists away from academia. That team plus top biotech execs and a $3B war chest make Altos one to watch in coming years. I
Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis Read More »
I wrote briefly a few months ago about Altos Labs. It’s a new kind of biotech institute that is focused on cellular reprogramming. Now we know much more and it’s clear this is a huge deal. What’s in this article What is Altos Labs? | Cellular rejuvenation | Reprogramming oldness | Challenges | Altos Strategies | Analysis of
All about Altos Labs and $3B cellular rejuvenation push Read More »
A piece on human tails and how we lost them caught my eye so I’ll start my weekly reads with that. This week I had the fewest Zoom meetings in ages, which allowed me to get more work done in my own lab and more reading. How about that? I even had some in-person meetings
Recommended reads: a tale of human tails, heart reprogramming, pericytes, microglia Read More »